
PFENYSEPharmaceuticals
$29.44
Up+$0.23 (+0.79%)today
Market closed · refreshes every 30sLast trade Oct 15, 4:00 PM EDT
Verizon and Pfizer pay generous dividends, and each has a different path to growth. Here's how income investors can lock in yield before year-end.
Key TakeawaysPfizer yields 6. 3% and GSK yields 4.
Investors are pricing Merck (MRK) stock at 5.5 times sales, compared with 3.1 for the S&P 500. Shareholders paying that premium need to understand exactly what they hold, and the drugmaker's priorities have changed. During the fiscal Q4 2024 call in February 2025, executives noted that conditions for the GARDASIL vaccine in China remained challenging. By the August 4, 2026 call, management emphasized something else. So what does management talk up now.
Money is leaving the AI trade and landing in healthcare, but one mRNA name is surging at a pace that leaves its closest peers far behind, and a clinical story from weeks ago may explain why.
Sign in to track your PFE shares and return.
Add to portfolioAbbVie is raising its outlook with Skyrizi and Rinvoq offsetting Humira losses. Pfizer is rebuilding its pipeline around obesity drugs and key readouts expected over the next year.
Altria's cigarettes kill hundreds of thousands of Americans every year, yet its stock is quietly outperforming the S&P 500 by a wide margin in 2024. The question investors now face says as much about ethics as it does about returns.
Johnson & Johnson (JNJ) stock trades at 29.1 times its earnings over the past twelve months, compared with 22.7 for the S&P 500. Investors paying that premium appear to be counting on more growth. The company raised its 2026 guidance on October 13, and Chief Executive Joaquin Duato pointed to one new product as one of its most transformative MedTech innovations. So which product is it.
CNBC Final Trades: Weiss picked 10-year Treasuries, Thomas chose XAR, Firestone favored TMO, and Terranova selected PFE.